During this segment, the panelists discuss treatment options for systemic lupus erythematosus (SLE) and recognize unmet treatment needs from the perspectives of the patient, provider, and payer. To improve patient outcomes, the panelists explore different ways in which treatment for SLE can be improved.
Hugh Fatodu, RPh, MBA, explains that agents currently used to treat SLE are accompanied with adverse events that affect patient adherence, and results of therapy have proven inconsistent amongst certain subgroups of patients. Therefore, clinicians currently question the ability of these agents to provide benefits to their patients.
Michelle Petri, MD, MPH, explains the ways in which long-term exposure of prednisone affects patient outcomes. Dr Petri also believes that a personalized treatment approach is necessary when treating patients.
And because long-term data is still lacking, Maria Lopes, MD, MS, believes that an early diagnosis of SLE is essential, as outcomes of severe SLE are more dangerous.